$DNA
Ginkgo Bioworks Holdings, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022017412 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $144.6M $148.5M $43.64M
YoY Change 231.42% 362.6%
Cost Of Revenue $63.91M $66.58M $17.11M
YoY Change 273.53% 382.45%
Gross Profit $80.71M $81.92M $26.53M
YoY Change 204.26% 350.09%
Gross Profit Margin 55.81% 55.16% 60.79%
Selling, General & Admin $438.4M $781.6M $34.44M
YoY Change 1173.02% 5959.12%
% of Gross Profit 543.23% 954.18% 129.83%
Research & Development $289.2M $985.0M $52.03M
YoY Change 455.8% 1509.52%
% of Gross Profit 358.32% 1202.48% 196.15%
Depreciation & Amortization $9.608M $8.003M $7.165M
YoY Change 34.1% 100.08% 13.19%
% of Gross Profit 11.9% 9.77% 27.01%
Operating Expenses $791.5M $1.767B $103.6M
YoY Change 664.16% 2284.14%
Operating Profit -$646.9M -$1.685B -$59.95M
YoY Change 979.17% 2913.84%
Interest Expense -$47.17M -$19.27M -$2.069M
YoY Change 2179.6% 3111.67%
% of Operating Profit
Other Income/Expense, Net -$23.71M $98.33M $5.050M
YoY Change -569.45% 873.53%
Pretax Income -$670.6M -$1.606B -$54.90M
YoY Change 1121.63% 3360.51%
Income Tax -$45.00K -$683.0K -$431.0K
% Of Pretax Income
Net Earnings -$668.8M -$1.601B -$53.94M
YoY Change 1139.92% 3312.91% 87.75%
Net Earnings / Revenue -462.48% -1077.93% -123.62%
Basic Earnings Per Share -$0.41 -$0.04
Diluted Earnings Per Share -$0.41 -$1.044M -$0.04
COMMON SHARES
Basic Shares Outstanding 1.621B 1.293B
Diluted Shares Outstanding 1.621B 1.293B

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.377B $1.550B $235.9M
YoY Change 483.8%
Cash & Equivalents $1.377B $1.550B $235.9M
Short-Term Investments
Other Short-Term Assets $38.72M $698.0K $17.07M
YoY Change 126.79% 2.65%
Inventory $8.102M $3.362M $2.716M
Prepaid Expenses $9.739M
Receivables $171.6M $131.5M $28.39M
Other Receivables $0.00 $13.76M $0.00
Total Short-Term Assets $1.599B $1.723B $284.1M
YoY Change 462.84% 303.96%
LONG-TERM ASSETS
Property, Plant & Equipment $176.2M $145.8M $145.9M
YoY Change 20.8% 20.04%
Goodwill $30.97M $21.31M
YoY Change 1047.66%
Intangibles $39.18M $21.64M
YoY Change 557.01%
Long-Term Investments $6.914M $13.19M $110.1M
YoY Change -93.72% -54.38%
Other Assets $53.02M $43.99M $25.44M
YoY Change 108.4% 685.12%
Total Long-Term Assets $395.4M $347.9M $303.0M
YoY Change 30.49% 39.96%
TOTAL ASSETS
Total Short-Term Assets $1.599B $1.723B $284.1M
Total Long-Term Assets $395.4M $347.9M $303.0M
Total Assets $1.994B $2.071B $587.0M
YoY Change 239.7% 206.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.46M $8.189M $2.767M
YoY Change 603.25% -41.06%
Accrued Expenses $70.06M $93.33M $47.02M
YoY Change 48.99% 205.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $135.0M $134.8M $81.09M
YoY Change 66.51% 84.05%
LONG-TERM LIABILITIES
Long-Term Debt $51.55M $22.28M $16.36M
YoY Change 215.11%
Other Long-Term Liabilities $36.11M $35.99M $133.8M
YoY Change -73.02% 1087.07%
Total Long-Term Liabilities $36.11M $35.99M $150.2M
YoY Change -75.96% 1087.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $135.0M $134.8M $81.09M
Total Long-Term Liabilities $36.11M $35.99M $150.2M
Total Liabilities $427.2M $503.6M $238.2M
YoY Change 79.33% 145.54%
SHAREHOLDERS EQUITY
Retained Earnings -$3.557B -$2.298B
YoY Change 391.14%
Common Stock $164.0K $161.0K
YoY Change 24.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.535B $1.505B $348.8M
YoY Change
Total Liabilities & Shareholders Equity $1.994B $2.071B $587.0M
YoY Change 239.7% 206.74%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income -$668.8M -$1.601B -$53.94M
YoY Change 1139.92% 3312.91% 87.75%
Depreciation, Depletion And Amortization $9.608M $8.003M $7.165M
YoY Change 34.1% 100.08% 13.19%
Cash From Operating Activities -$99.30M -$165.5M -$34.91M
YoY Change 184.43% 178.97% -31.84%
INVESTING ACTIVITIES
Capital Expenditures -$9.573M -$5.114M -$24.03M
YoY Change -60.17% -126.35% -346.76%
Acquisitions
YoY Change
Other Investing Activities -$5.090M $9.342M $103.0K
YoY Change -5041.75% -199.17% 930.0%
Cash From Investing Activities -$14.66M $4.228M -$23.93M
YoY Change -38.73% -114.67% 145.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -954.0K -11.04M -2.123M
YoY Change -55.06% 6035.0% -103.11%
NET CHANGE
Cash From Operating Activities -99.30M -165.5M -34.91M
Cash From Investing Activities -14.66M 4.228M -23.93M
Cash From Financing Activities -954.0K -11.04M -2.123M
Net Change In Cash -114.9M -172.4M -60.96M
YoY Change 88.49% 95.08% -936.28%
FREE CASH FLOW
Cash From Operating Activities -$99.30M -$165.5M -$34.91M
Capital Expenditures -$9.573M -$5.114M -$24.03M
Free Cash Flow -$89.72M -$160.4M -$10.88M
YoY Change 724.9% 103.72% -82.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001830214
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40097
dei Entity Registrant Name
EntityRegistrantName
GINKGO BIOWORKS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2652913
dei Entity Address Address Line1
EntityAddressAddressLine1
27 Drydock Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
8th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
422-5362
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1377152000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1550004000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
171624000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
131544000
CY2022Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
3253000
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
4598000
CY2022Q2 us-gaap Inventory Net
InventoryNet
8102000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3362000
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
6500000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38717000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33537000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
1598848000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1723045000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
176221000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145770000
CY2022Q2 us-gaap Investments
Investments
89068000
CY2021Q4 us-gaap Investments
Investments
102037000
CY2022Q2 dna Equity Method Investment
EquityMethodInvestment
6914000
CY2021Q4 dna Equity Method Investment
EquityMethodInvestment
13194000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
39180000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21642000
CY2022Q2 us-gaap Goodwill
Goodwill
30973000
CY2021Q4 us-gaap Goodwill
Goodwill
21312000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53015000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43990000
CY2022Q2 us-gaap Assets
Assets
1994219000
CY2021Q4 us-gaap Assets
Assets
2070990000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
19459000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8189000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
13089000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
12502000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
45504000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33240000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
70059000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
93332000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
135022000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
134761000
CY2022Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
20214000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
18746000
CY2022Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
133006000
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
148319000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
156981000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
155991000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
51545000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
22283000
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
27294000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
135838000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
36107000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35992000
CY2022Q2 us-gaap Liabilities
Liabilities
427163000
CY2021Q4 us-gaap Liabilities
Liabilities
503611000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
164000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
161000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5098018000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3804844000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3557255000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2297925000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5496000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1715000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1535431000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1505365000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
31625000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
62014000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1567056000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1567379000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1994219000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2070990000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144618000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43636000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
313023000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87733000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
289188000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52031000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
611908000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
111616000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
438427000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34440000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
873195000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52367000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
791526000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
103581000
us-gaap Operating Expenses
OperatingExpenses
1634446000
us-gaap Operating Expenses
OperatingExpenses
204793000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-646908000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-59945000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1321423000
us-gaap Operating Income Loss
OperatingIncomeLoss
-117060000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1674000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-478000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1277000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-953000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10166000
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4346000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31053000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-32970000
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-38673000
CY2021Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
2755000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-38223000
us-gaap Gain Loss On Investments
GainLossOnInvestments
15377000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-23509000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-108544000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q2 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2021Q2 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
15900000
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-51000
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
7119000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1586000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
5774000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23707000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5050000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58031000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12772000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-670615000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54895000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1263392000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129832000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-431000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-229000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-590000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-670570000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-54464000
us-gaap Profit Loss
ProfitLoss
-1263163000
us-gaap Profit Loss
ProfitLoss
-129242000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1745000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-523000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3833000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1732000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-668825000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-53941000
us-gaap Net Income Loss
NetIncomeLoss
-1259330000
us-gaap Net Income Loss
NetIncomeLoss
-127510000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1620703542
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1620703542
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1292538294
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1292538294
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1614138189
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1614138189
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1291416874
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1291416874
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-670570000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-54464000
us-gaap Profit Loss
ProfitLoss
-1263163000
us-gaap Profit Loss
ProfitLoss
-129242000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3141000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3781000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3141000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3781000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-673711000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54464000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1266944000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129242000
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7973000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10962000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
21501000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
23622000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1614048000
CY2022Q2 dna Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units
IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits
2000
CY2022Q2 dna Issuance Of Common Stock For Business Acquisitions
IssuanceOfCommonStockForBusinessAcquisitions
20128000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606589000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3141000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-670570000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1567056000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1567379000
dna Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units
IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits
78000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-981000
dna Issuance Of Common Stock For Business Acquisitions
IssuanceOfCommonStockForBusinessAcquisitions
20128000
dna Deconsolidation Of Subsidiary Note4
DeconsolidationOfSubsidiaryNote4
-28783000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1276179000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3781000
us-gaap Profit Loss
ProfitLoss
-1263163000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1567056000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
395569000
CY2021Q2 dna Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units
IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits
12000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
150000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14519000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-54464000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
355786000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
470052000
dna Issuance Of Common Stock Options Value And Vesting Of Restricted Stock Units
IssuanceOfCommonStockOptionsValueAndVestingOfRestrictedStockUnits
39000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
300000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14637000
us-gaap Profit Loss
ProfitLoss
-129242000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
355786000
us-gaap Profit Loss
ProfitLoss
-1263163000
us-gaap Profit Loss
ProfitLoss
-129242000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19096000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12794000
us-gaap Share Based Compensation
ShareBasedCompensation
1259336000
us-gaap Share Based Compensation
ShareBasedCompensation
14637000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31053000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-32970000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-38223000
us-gaap Gain Loss On Investments
GainLossOnInvestments
15377000
dna Non Cash Equity Consideration
NonCashEquityConsideration
-18139000
dna Non Cash Equity Consideration
NonCashEquityConsideration
0
dna Changes In Fair Value Of Loans Receivable
ChangesInFairValueOfLoansReceivable
292000
dna Changes In Fair Value Of Loans Receivable
ChangesInFairValueOfLoansReceivable
-4384000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-108544000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
15900000
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1162000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-510000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
dna Accounts Receivable From Related Parties
AccountsReceivableFromRelatedParties
-1345000
dna Accounts Receivable From Related Parties
AccountsReceivableFromRelatedParties
-3590000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
38598000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
6479000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4973000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4854000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4740000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-20000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
419000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
55000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10650000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7321000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-12758000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
19139000
dna Deferred Revenue From Related Parties
DeferredRevenueFromRelatedParties
-14667000
dna Deferred Revenue From Related Parties
DeferredRevenueFromRelatedParties
-9995000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19708000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6067000
us-gaap Straight Line Rent
StraightLineRent
-1468000
us-gaap Straight Line Rent
StraightLineRent
-914000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3989000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
555000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119195000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83042000
dna Cash Acquired In Acquisition
CashAcquiredInAcquisition
1440000
dna Cash Acquired In Acquisition
CashAcquiredInAcquisition
0
dna Purchase Of Convertible Note
PurchaseOfConvertibleNote
-6500000
dna Purchase Of Convertible Note
PurchaseOfConvertibleNote
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13153000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45969000
dna Purchase Of Non Marketable Equity Securities
PurchaseOfNonMarketableEquitySecurities
3691000
dna Purchase Of Non Marketable Equity Securities
PurchaseOfNonMarketableEquitySecurities
0
us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
28772000
us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1210000
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
28000
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
202000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50648000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46977000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
39000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
981000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
720000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
448000
dna Contingent Consideration Payment
ContingentConsiderationPayment
-521000
dna Contingent Consideration Payment
ContingentConsiderationPayment
0
us-gaap Deferred Purchased Power Costs
DeferredPurchasedPowerCosts
0
us-gaap Deferred Purchased Power Costs
DeferredPurchasedPowerCosts
2147000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2146000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2556000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-104000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-172093000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-132575000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1550004000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
380801000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
42924000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5076000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1592928000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385877000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1377152000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235893000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
43683000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
17409000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1420835000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
253302000
dna Purchases Of Equipment Through Capital Leases
PurchasesOfEquipmentThroughCapitalLeases
1012000
dna Purchases Of Equipment Through Capital Leases
PurchasesOfEquipmentThroughCapitalLeases
1981000
dna Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
6741000
dna Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
3477000
dna Equity Received In Related Parties
EquityReceivedInRelatedParties
8873000
dna Equity Received In Related Parties
EquityReceivedInRelatedParties
24595000
dna Convertible Financial Instruments Received For Foundry Services
ConvertibleFinancialInstrumentsReceivedForFoundryServices
11939000
dna Convertible Financial Instruments Received For Foundry Services
ConvertibleFinancialInstrumentsReceivedForFoundryServices
0
dna Purchase Of Non Cash Marketable Equity Securities
PurchaseOfNonCashMarketableEquitySecurities
3423000
dna Purchase Of Non Cash Marketable Equity Securities
PurchaseOfNonCashMarketableEquitySecurities
0
dna Lease Financing Obligation For Build To Suit Lease
LeaseFinancingObligationForBuildToSuitLease
29482000
dna Lease Financing Obligation For Build To Suit Lease
LeaseFinancingObligationForBuildToSuitLease
0
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
17015000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0
dna Contingent Consideration For Business Acquisition
ContingentConsiderationForBusinessAcquisition
12306000
dna Contingent Consideration For Business Acquisition
ContingentConsiderationForBusinessAcquisition
0
dna Deferred Offering Costs In Accounts Payable And Accrued Expense
DeferredOfferingCostsInAccountsPayableAndAccruedExpense
0
dna Deferred Offering Costs In Accounts Payable And Accrued Expense
DeferredOfferingCostsInAccountsPayableAndAccruedExpense
4091000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> no effect on the reported results of operations.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the condensed consolidated financial statements. Estimates used in the preparation of these condensed consolidated financial statements include, among others, revenue recognition, stock-based compensation, the fair value of assets acquired and liabilities assumed in a business combination, the fair value of non-cash consideration received from customers, the fair value of loans receivable, the fair value of certain investments including equity method investments, the fair value of warrant liabilities, the allocation of equity method investment losses under the hypothetical liquidation at book value (“HLBV”) method, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">accrued expenses and income taxes. Actual results could differ materially from those estimates.</span></p>
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4051107
CY2022Q2 dna Estimated Fair Value
EstimatedFairValue
1900000
CY2022Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
800000
CY2022Q2 dna Milestone Payments
MilestonePayments
25000000.0
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
1430000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
144000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
10000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
146000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
21100000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
11001000
CY2022Q2 dna Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses
-29000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
104000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
4377000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
29321000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.722
dna Years To Maturity
YearsToMaturity
P0Y4M17D
dna Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Adjsuted Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskAdjsutedInterestRate
33.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.855
CY2021 dna Years To Maturity
YearsToMaturity
P0Y10M17D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
39444000
CY2021Q2 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
17409000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1420835000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
253302000
CY2022Q2 us-gaap Investments
Investments
89068000
CY2021Q4 us-gaap Investments
Investments
102037000
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
6914000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
13194000
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-38673000
CY2021Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
2755000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-38223000
us-gaap Gain Loss On Investments
GainLossOnInvestments
15377000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10166000
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4346000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-31053000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-32970000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1377152000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235893000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
4239000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7524000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3264000
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
863000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
64000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
0
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
50000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
285000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
16000
CY2022Q2 us-gaap Inventory Net
InventoryNet
8102000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3362000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
254433000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
206822000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
78212000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61052000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
176221000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145770000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15800000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1779814217
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1635634269
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15800000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1690990815
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1611392152
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1259336000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14637000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22454663
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
651096
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.82
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3872794
dna Employer Payroll Taxes
EmployerPayrollTaxes
7000000.0
CY2021Q2 dna Employer Payroll Taxes
EmployerPayrollTaxes
0
dna Employer Payroll Taxes
EmployerPayrollTaxes
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19232965
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y1M2D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43731000
CY2021Q4 us-gaap Goodwill
Goodwill
21312000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
11001000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1389000
dna Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
49000
CY2022Q2 us-gaap Goodwill
Goodwill
30973000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1700000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
3400000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606515000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14519000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.02
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
18530087
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y9M18D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
43731000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20300000
dna Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Value Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue
1200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0325
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
200000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
200000
CY2021Q4 us-gaap Share Price
SharePrice
12.50
CY2022Q2 dna Foundry Revenue Percentage
FoundryRevenuePercentage
1
CY2021Q2 dna Foundry Revenue Percentage
FoundryRevenuePercentage
1
dna Foundry Revenue Percentage
FoundryRevenuePercentage
1
dna Foundry Revenue Percentage
FoundryRevenuePercentage
1
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
25200000
CY2021Q4 dna Contract Liabilities
ContractLiabilities
189200000
dna Number Of Additional Common Units Received
NumberOfAdditionalCommonUnitsReceived
7245000
CY2021 dna Number Of Allocated Performance Obligations
NumberOfAllocatedPerformanceObligations
10
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
18500000
CY2020Q4 dna Contract Liabilities
ContractLiabilities
128500000
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
53800000
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
21100000
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Year1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1
2022
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Year1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionYear1
2026
CY2022Q2 dna Employer Payroll Taxes
EmployerPayrollTaxes
800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
448163835
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
182188894
CY2022Q2 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
3253000
CY2021Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
4598000
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
146095000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
160821000
CY2022Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7973000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10962000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
21501000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
23622000

Files In Submission

Name View Source Status
0000950170-22-017412-index-headers.html Edgar Link pending
0000950170-22-017412-index.html Edgar Link pending
0000950170-22-017412.txt Edgar Link pending
0000950170-22-017412-xbrl.zip Edgar Link pending
dna-20220630.htm Edgar Link pending
dna-20220630.xsd Edgar Link pending
dna-ex10_1.htm Edgar Link pending
dna-ex10_2.htm Edgar Link pending
dna-ex10_3.htm Edgar Link pending
dna-ex10_4.htm Edgar Link pending
dna-ex31_1.htm Edgar Link pending
dna-ex31_2.htm Edgar Link pending
dna-ex32_1.htm Edgar Link pending
dna-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
dna-20220630_def.xml Edgar Link unprocessable
dna-20220630_lab.xml Edgar Link unprocessable
dna-20220630_cal.xml Edgar Link unprocessable
dna-20220630_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dna-20220630_pre.xml Edgar Link unprocessable